Close

Rexahn Pharma (RNN) Names Douglas J. Swirsky as President and CFO

January 4, 2018 9:05 AM EST Send to a Friend
Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login